The firms had planned to develop the assay on Biocartis' Idylla platform, which would have allowed customers to perform the assay locally in their own lab facilities.
Avapritinib is sold by Blueprint Medicines as Ayvakit for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation.
The companies are positioning the test, called SeptiCyte Rapid, for use in triaging COVID-19 patients who could be at greater risk for progressing to sepsis.
The PCR viral load test runs on the Cobas 6800/8800 systems and has been calibrated to the World Health Organization International Standard, Roche said.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
